A Randomized, Double-Blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin.
Latest Information Update: 26 Feb 2017
Price :
$35 *
At a glance
- Drugs Fenofibrate/metformin (Primary) ; Metformin
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms FAME-METFO
- Sponsors Abbott Laboratories; Fournier Pharma
- 05 May 2009 Actual end date added as 1 Mar 2009 as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Apr 2008 Status changed from recruiting to in progress.